Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy
Completed
- Conditions
- Cardiac Allograft Vasculopathy
- Registration Number
- NCT04791852
- Lead Sponsor
- Puerta de Hierro University Hospital
- Brief Summary
Cross-sectional study. We will prospectively obtain ddcf-DNA levels in all patients who undergo routine coronary angiography \> 1 year after HT. Our main goal is to evaluate the performance of Donor-derived Cell Free DNA (ddcf-DNA) as a biomarker of CAV.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 94
Inclusion Criteria
- Patients over 18 and under 80 years old, HT > 1 year ago
Exclusion Criteria
- Patients under 18 or over 80 years old
- Multiorgan transplant
- History of acute cellular rejection ≥ 1R or antibody mediated rejection in the previous 6 months
- Concomitant infection by CMV
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Performance of the biomarker for the diagnosis of CAV 2 years Determine the performance of this biomarker in this situation using receiver-operator characteristics analysis.
Correlation between ddcf-DNA and CAV 2 years Correlation between ddcf-DNA levels and the presence of any degree of CAV (CAV0 vs CAV1, 2, or 3)
- Secondary Outcome Measures
Name Time Method Correlation of ddcf-DNA with the different degrees of CAV (0, 1, 2 and 3) 2 years Correlation of ddcf-DNA with the different degrees of CAV (0, 1, 2 and 3)
Correlation of ddcf-DNA with other biomarkers (NTproBNP and troponin I) 2 years Correlation of ddcf-DNA with other biomarkers (NTproBNP and troponin I)
Trial Locations
- Locations (1)
University Hospital Puerta de Hierro
🇪🇸Majadahonda, Madrid, Spain